TissueGen‘s chief scientist and co-founder, Kevin Nelson, told Drug Delivery Business News the story behind the company he founded in 2000 and its drug delivery technology, the Elute fiber.
DDBN: How did TissueGen get its start?
Nelson: In 1996, while faculty in biomedical engineering at The University of Texas at Arlington, I was working with Dr. Robert Eberhart at the University of Texas Southwestern Medical Center at Dallas. Together, we collaborated with a team to develop a biodegradable vascular stent that had the potential to deliver a live virus to the arterial wall. Simultaneously, I was working with Dr. Nathan Schwade at the Callier Center, Texas Woman’s University to develop a method to deliver non-toxic drugs to the inner ear. The cross-pollination of these two projects, developing fibers for stents and microspheres for otic delivery, inspired me to investigate delivering drugs directly from an extruded fiber.